Inspire Medical Systems, Inc. (INSP) Balance Sheet

The growth in assets appears driven largely by cash accumulation and a rising PPE base, though cash balances have fluctuated materially quarter to quarter. Equity has grown from $638.1M to $826.9M over the period, which may indicate capital retention or equity issuance, but the reported figures alone do not confirm the source. Investors should monitor whether this expansion is sustained once operating losses are reflected in the cash line.

Debt has remained in a narrow $24.5M to $33.5M band for most of the period, with a temporary spike to $62.2M in 2025Q4 that reverted in the following quarter. This pattern suggests short-term borrowing rather than structural leverage, though the composition of that spike is not disclosed in the supplied data. Low leverage meaningfully reduces near-term refinancing exposure, but it does not address the underlying question of whether operating losses can be sustained.

Cash rebounded from $98.9M in 2026Q1 to $190.8M in 2026Q3, which appears to reflect a combination of working capital timing and possible financing inflows that are not fully disclosed here. The current ratio has compressed from 9.25 in 2024Q2 to the mid-single digits, suggesting that current liabilities have grown faster than current assets in recent quarters. Investors should watch whether the liquidity cushion holds as operating losses continue.

The improvement in retained earnings is substantially larger than the quarterly net income in several periods, which may indicate non-operating or tax-related contributions rather than core operating profit. Equity growth therefore appears to rely partly on items that may not recur. The persistent accumulated deficit, despite recent gains, warrants monitoring for signs of dilution or sustained losses eroding the equity base.